Lanthanum-Based Metal Organic Framework (La-Mof) Use of 3,4-Dihydroxycinnamic Acid As Drug Delivery System Linkers in Human Breast Cancer Therapy

Lanthanum-Based Metal Organic Framework (La-Mof) Use of 3,4-Dihydroxycinnamic Acid As Drug Delivery System Linkers in Human Breast Cancer Therapy Publisher

Safinejad M¹ ; Rigi A² ; Zeraati M³ ; Heidary Z⁴ ; Jahani S⁵ ; Chauhan NPS⁶ ; Sargazi G⁵

Source: BMC Chemistry Published:2022

Abstract

Metal organic frameworks (MOFs) have received a lot of attention in the research community due to their unique physical properties, which make them ideal materials for targeted drug delivery systems. In this paper, we describe the synthesis of a non-toxic La-based MOF with 3,4-dihydroxycinnamic acid (3,4-DHCA) as a linker. Scanning electron microscopy (SEM), transmission electron microscopy (TEM), energy dispersive spectroscopy (EDS), fourier transform infrared (FTIR) spectroscopy, thermogravimetric analysis (TGA), nitrogen adsorption–desorption measurements, and X-ray powder diffraction (XRD) have all been used to characterize it thoroughly. The La-based MOF showed good biocompatibility with the human breast cancer cell line MDA-MB-468. The ability of 3,4-DHCA to treat MDA-MB-468 cells was confirmed by 40.35% cell viability with La-based MOF. Based on the findings, La-based MOF can be recommended as a promising candidate for anticancer delivery. © 2022, The Author(s).

Related Docs

View other Related Docs

1. Mof As Nanoscale Drug Delivery Devices: Synthesis and Recent Progress in Biomedical Applications, Journal of Drug Delivery Science and Technology (2023)

2. A Review of Recent Developments of Metal–Organic Frameworks As Combined Biomedical Platforms Over the Past Decade, Advances in Colloid and Interface Science (2023)

3. Adsorption Behavior of a Gd-Based Metal-Organic Framework Toward the Quercetin Drug: Effect of the Activation Condition, ACS Omega (2022)

Experts (# of related papers)

View all Related Experts

Mohammad Sharifzadeh (2)

Mohammad Mahdavi (2)

Style	Citing Format
MLA	Safinejad M, et al.. "Lanthanum-Based Metal Organic Framework (La-Mof) Use of 3,4-Dihydroxycinnamic Acid As Drug Delivery System Linkers in Human Breast Cancer Therapy." BMC Chemistry, vol. 16, no. 1, 2022, pp. -.
APA	Safinejad M, Rigi A, Zeraati M, Heidary Z, Jahani S, Chauhan NPS, Sargazi G (2022). Lanthanum-Based Metal Organic Framework (La-Mof) Use of 3,4-Dihydroxycinnamic Acid As Drug Delivery System Linkers in Human Breast Cancer Therapy. BMC Chemistry, 16(1), -.
Chicago	Safinejad M, Rigi A, Zeraati M, Heidary Z, Jahani S, Chauhan NPS, Sargazi G. "Lanthanum-Based Metal Organic Framework (La-Mof) Use of 3,4-Dihydroxycinnamic Acid As Drug Delivery System Linkers in Human Breast Cancer Therapy." BMC Chemistry 16, no. 1 (2022): -.
Harvard	Safinejad M et al. (2022) 'Lanthanum-Based Metal Organic Framework (La-Mof) Use of 3,4-Dihydroxycinnamic Acid As Drug Delivery System Linkers in Human Breast Cancer Therapy', BMC Chemistry, 16(1), pp. -.
Vancouver	Safinejad M, Rigi A, Zeraati M, Heidary Z, Jahani S, Chauhan NPS, et al.. Lanthanum-Based Metal Organic Framework (La-Mof) Use of 3,4-Dihydroxycinnamic Acid As Drug Delivery System Linkers in Human Breast Cancer Therapy. BMC Chemistry. 2022;16(1):-.
BibTex	@article{ author = {Safinejad M and Rigi A and Zeraati M and Heidary Z and Jahani S and Chauhan NPS and Sargazi G}, title = {Lanthanum-Based Metal Organic Framework (La-Mof) Use of 3,4-Dihydroxycinnamic Acid As Drug Delivery System Linkers in Human Breast Cancer Therapy}, journal = {BMC Chemistry}, volume = {16}, number = {1}, pages = {-}, year = {2022} }
RIS	TY - JOUR AU - Safinejad M AU - Rigi A AU - Zeraati M AU - Heidary Z AU - Jahani S AU - Chauhan NPS AU - Sargazi G TI - Lanthanum-Based Metal Organic Framework (La-Mof) Use of 3,4-Dihydroxycinnamic Acid As Drug Delivery System Linkers in Human Breast Cancer Therapy JO - BMC Chemistry VL - 16 IS - 1 SP - EP - PY - 2022 ER -

Science Communicator Platform

Authors

Abstract